PT  - JOURNAL ARTICLE
AU  - GIULIA PASELLO
AU  - GIUSEPPE MARULLI
AU  - VALENTINA POLO
AU  - CRISTIANO BREDA
AU  - LAURA BONANNO
AU  - LUCIO LOREGGIAN
AU  - FEDERICO REA
AU  - ADOLFO FAVARETTO
TI  - Pemetrexed plus Carboplatin or Cisplatin as Neoadjuvant Treatment of Operable Malignant Pleural Mesothelioma (MPM)
DP  - 2012 Dec 01
TA  - Anticancer Research
PG  - 5393--5399
VI  - 32
IP  - 12
4099  - http://ar.iiarjournals.org/content/32/12/5393.short
4100  - http://ar.iiarjournals.org/content/32/12/5393.full
SO  - Anticancer Res2012 Dec 01; 32
AB  - Aim: The objective of this study was the retrospective evaluation of tolerability and activity of pemetrexed with carboplatin (AC) or cisplatin (AP) as neoadjuvant chemotherapy in a consecutive series of patients with malignant pleural mesothelioma (MPM). Patients and Methods: Patients with operable MPM received three cycles of AC or AP followed by surgery and radiotherapy. Results: Since 2005, 51 patients have been treated with AC (27) and AP (24). We observed higher incidence of grade 3 anaemia, cumulative grade 2-3 asthenia and worsening of performance status in the AP group. Response to AC and AP were; complete: 4% vs. 0%, partial: 18% vs. 17%, stable disease: 74% vs. 79%, progressive disease: 4%; the resection rate was 81% vs. 79%. Conclusion: AC and AP are active and feasible neoadjuvant regimens. Progression-free survival, response, disease control and resection rate were similar in the two treatment groups. The lower tolerability to AP treatment could impair the clinical condition of patients undergoing surgery.